Foamix foam preparation FMX103 treatment of severe papules pustules acne reaches two major therapeutic endpoints

papules pustules acne is a chronic skin disease that causes inflammatory lesions (pimpand and pustules) on the nose, cheeks, chin and forehead that can cause socio-psychological burdens such as distress, low anxiety and low self-esteem, and negative effects on quality of lifeToday, the israeli bio
pharmaceutical(Pharmaceuticals announced that its 1.5 percent minocycline foam, FMX103), has reached two major therapeutic ends in two Phase 3trials (and FX2016-12) for the treatment of severe papules puma acnerelated studies
FX2016-11 and FX2016-12 are two phase 3 trials of the same phase of randomized, double-blind, vector-controlled, with a total of 1,522 patients with moderate lyphopreoma puspersery acne involving more than 100 institutions in the United StatesPatients were randomly divided into two groups on a 2:1 scale, receiving one-time FMX103 or carrier foam preparationtwo main therapeutic endpoints were: changes in absolute value seistic disease index compared to baselines at week 12, and percentage of patients who achieved at least 2 points improvement in the overall assessment score (IGA) 0 or 1 and baselinein addition,, the trial assessed the safety and resistance of FMX103The results of the12-week trial showed that FMX103 significantly improved the severity of the diseaseIn the trial FX2016-11, the proportion of patients in the FMX103 group who achieved a significant improvement in IGA was 52.1%, compared with 43% in the vector group; Inflammatory lesions index also improved significantly in both trialsin the trial FX2016-11, the inflammatory lesions index in the FMX103 group decreased by -17.57, compared with -15.65 in the vector group, and in the trial FX2016-12, the comparison was -18.54 vs14.88In addition, the safety and resistance results of THE FMX103 have been shown to be good